A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®

Amgen0 个研究点目标入组 2,423 人开始时间: 2002年9月1日最近更新: 2009年3月25日

适应症

试验速览

阶段: 4 期
状态: 已完成
发起方: Amgen
入组人数: 2,423
主要终点: Patient reported outcomes

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

The purpose of this trial is to prospectively assess the relationship between changes in hemoglobin (hgb) and changes in symptom burden associated with anemia in cancer patients receiving chemotherapy supported with Aranesp®.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Subjects with nonmyeloid malignancy(ies)
•Anemia (hgb less than or equal to 11.0 g/dL) due to cancer and chemotherapy

排除标准

•Subjects with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndromes (MDS)
•Unstable cardiac disease or anemia due to other causes

结局指标

主要结局

Patient reported outcomes

次要结局

Changes in hemoglobin endpoints and RBC transfusion requirements

研究者

发起方

Amgen

申办方类型

Industry

相似试验

招募中

4 期

Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)Heart FailureAnemia

NCT04707261Xiangtan Central Hospital1,990

已完成

不适用

A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)Renal Anemia of Chronic Kidney Disease

NCT01756612Hoffmann-La Roche551

已完成

不适用

MELD ESAS Evolution: Assessment of the Symptomatic Burden of Patients With Advanced Chronic Liver DiseasePalliative CareEnd Stage Liver DIsease

NCT06181474Unidade Local de Saúde de Matosinhos, EPE44

已完成

2 期

Heart Failure and AnemiaHeart FailureAnemia

NCT00049985Amgen300

已完成

2 期

A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.Chronic Kidney DiseaseAnemia

NCT00212875Johnson & Johnson Pharmaceutical Research & Development, L.L.C.267